China Metastatic Liver Cancer Clinical Registry Cohort Database
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Standard of Care for Metastatic Liver Cancer.
- Who it may be relevant to
- Registry conditions: Liver Metastases, Metastases to Liver, Liver Cancer, Neoplasms. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study is led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close collaboration with multiple participating centers nationwide. The primary objective is to establish a standardized, large-scale clinical cohort database specifically for metastatic liver cancer. By collecting comprehensive data on patient demographics, primary tumor characteristics, systemic therapies, and local interventions, this registry aims to elucidate the clinical patterns and prognostic factors of secondary liver malignancies. This database will serve as a robust platform for conducting high-quality real-world studies and advancing evidence-based clinical research in the management of metastatic liver cancer.
Interventions
- Procedure Standard of Care for Metastatic Liver Cancer
In this observational patient registry, no specific interventional procedure is assigned by the investigators. Patients included in the database receive standard clinical management and treatments for metastatic liver cancer according to current clinical guidelines and physician's discretion. These procedures may include hepatectomy, ablation, transarterial chemoembolization (TACE), systemic chemotherapy, targeted therapy, or immunotherapy. This registry aims to evaluate the real-world effective
Primary outcome measures
- Overall Survival [Time frame: Up to 10 years]
Secondary outcome measures (2)
- Progression-Free Survival [Time frame: Up to 10 years]
- Treatment-Related Adverse Events [Time frame: Within 90 days post-treatment]
Eligibility criteria
Inclusion criteria
- Patients with histologically or radiologically confirmed metastatic liver cancer.
- Age ≥ 18 years.
- Patients who have voluntarily signed the informed consent form.
- Patients with complete baseline clinical data.
Exclusion criteria
- Patients with primary liver cancer (e.g., hepatocellular carcinoma).
- Patients with other malignant tumors that may interfere with the evaluation of liver metastasis.
- Patients who have previously participated in other interventional clinical trials.
- Patients with severe cognitive disorders or communication barriers that prevent informed consent.
- Patients with incomplete or missing key clinical data.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
China · 3 centers
- The First Affiliated Hospital of Bengbu Medical University — Bengbu
- The First Affiliated Hospital of USTC (Anhui Provincial Hospital) — Hefei
- The Affiliated Hospital of Qingdao University — Qingdao
Identifiers
NCT: NCT07602504 · 2025KY534